ArticleESMO real world data and digital oncology2025
Real-word evidence in anti-VEGF naive patients treated with pazopanib for metastatic renal cell carcinoma (mRCC), the APOLON Study.
Article in ESMO real world data and digital oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitor-based combinations have become the standard of care for treatment-naive metastatic renal cell carcinoma Material and methods: APOLON is a non-interventional, multicentric prospective study with mRCC patients receiving frontline pazopanib treatment, designed to assess progression-free survival (PFS), overall survival (OS), objective response rate, tolerability, and subsequent post-pazopanib therapy sequences. Result: The 217 patients were 71.0% male, with a median age of 69.6 years, an Eastern Cooperative Oncology Group performance status ≥2 in 17.6%, and mRCC with a favourable (27.1%), intermediate (52.1%) or poor (20.8%) IMDC score. Metastases were mainly located in lung (64.1%), bone (28.6%), mediastinal (18%)/abdominal (17.1%) lymph nodes. Median PFS was 10.6 months [95% confidence interval (CI) 9-12.5 months], similarly in patients aged <65 years with PFS 11.3 months (95% CI 6.8-16.1 months) and aged ≥65 years with PFS 10.1 months (95% CI 9.0-12.4 months). The median PFS was 17.1 months (95% CI 9.9-23.2 months), 12.5 months (95% CI 9.0-15.4 months) and 6.2 months (95% CI 3.5-9.5 months) in patients with a favourable, intermediate, and poor IMDC score, respectively. The median OS was 29.1 months (95% CI 24.3-41.3 months). Objective response rate was 48.3% with a complete response in 6 (3.5%) and a partial response in 77 patients (44.8%). Grade 3/4 adverse events were reported in 45.8% of patients. No safety signals were newly identified. Conclusion: The APOLON study confirmed pazopanib effectiveness and safety in patients with mRCC in a real-world setting. The efficacy remained significant in patients aged ≥65 years and was highly associated with the risk score.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.